MASLD Research Center

Great discussions at the UCSD GI and Hepatology 17th Annual Research Retreat. Team members from the MASLD Research Center presented their work. @UCSD_GI @MonicaTincopa @AjmeraVeeral @LuisAntonioDiaz @DrLoomba

And just like that… The time you do a Meet the Professor session on #NITs & therapeutics in #MASLD & #MASH @DDWMeeting with your former fellowship director. Great session discussing diagnosis, risk stratification & treatment🙌

As #DDW2026 kicks off, we’re proud to highlight our @UCSD_GI team presenting oral and poster sessions. Grateful for the collaboration and innovation that made this possible. Looking forward to an inspiring conference!#MASLD @MASLDResearch @DrLoomba

1/ New review in @HepCommJournal by @PojsakornDan : The global epidemiology of alcohol-associated liver disease (ALD). ALD is one of the most preventable causes of liver-related death worldwide — and the burden is set to surge. A thread on what every clinician should know. 🧵

The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligence - JHEP Reports jhep-reports.eu/article/S2589-…

Advances in genomic discovery are bringing precision medicine closer to the bedside. In @AGA_Gastro, we explore the promise and pitfalls of genetics and emerging personalized therapeutics in hepatology. @AjmeraVeeral, V Chen, R Reddy @AmerGastroAssn gastrojournal.org/article/S0016-…

New! Online now: The many pathways driving liver inflammation in MASH dlvr.it/TRgMBy

1/6 🧵 In patients with ALD referred for early LT: cardiometabolic risk factors (CMRF) matter. In this multicentre cohort, CMRFs were linked to a lower chance of hepatic recompensation after referral. #LiverTwitter @UCSD_GI @MASLDResearch @AjmeraVeeral @DeepikaDevuniMD

Our review on RLSE in MASH -Noninvasive surrogate endpoints of adverse outcomes,... : Hepatology journals.lww.com/hep/abstract/9… @AASLDtweets @EASLnews @BavenoCoop @APASLnews @INASL_Liver @QAnstee @VWSWong @AparnaGoelMD

Had a brilliant day as a visiting professor at PGIMER Chandigarh- thanks to @ajay_duseja for hosting me! Really enjoyed the research presentations by fellows & ward rounds followed by evening liver society forum! @drnipunverma @MASLDResearch @AASLDPresident @EASLnews @UCSDHealth

Great CME hosted by Department of Hepatology, @pgichd. Insightful discussion on recent advances in MASLD by @DrLoomba Always inspiring to see the impactful work being led by @ajay_duseja . As a trainee, grateful for the opportunity to learn from leaders in the field. @drsuniltaneja @atulsachdeva @drnipunverma @drbabupgi

A new international consensus published in @AGA_Gastro establishes a unified framework for diagnosing and staging liver disease in α-1 antitrypsin deficiency. Read more here: ow.ly/hl9350Yn4OZ @DrLoomba @MattiasMandorf1 @AleksanderKrag @PaulYKwo

Congratulations @f_tavaglione at @MASLDResearch @UCSD_GI for a fantastic paper- great to collaborate with @hanneshgstrm @EASLnews @AASLDtweets @AASLDPresident @AmerGastroAssn @AGA_Gastro health.ucsd.edu/news/press-rel…

Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing jhep-reports.eu/article/S2589-… @f_tavaglione nice paper! @AASLDtweets @EASLnews @MASLDResearch @UCSD_GI @UCSDHealth @AmerGastroAssn

#ColorectalCancer is increasing among younger adults, making awareness & early screening more important than ever. Rohit Loomba, MD, #UCSDHealth, joined @CBS8 to discuss why screening matters, plus the key signs and symptoms you shouldn’t ignore.@DrLoomba cbs8.com/video/news/loc…

Clinical utility of a 50% and 30% decline in MRI-PDFF in predicting fibrosis improvement in metabolic dysfunction-associated steatohepatitis - CGH cghjournal.org/article/S1542-…

Our new paper on comparative efficacy of MASH therapies in cirrhosis- FGF-21, and combination therapies may be useful in reversing MASH cirrhosis- @AASLDtweets @EASLnews @DrHuangDQ @MASLDResearch @UCSD_GI Alimentary Pharmacology & Therapeutics | onlinelibrary.wiley.com/doi/10.1111/ap…

Tonight talking about MASH including new treatments- ⁦@AjmeraVeeral⁩ in San Diego kickstarting with natural history and NITs in MASH ⁦@AASLDtweets⁩ ⁦@EASLnews⁩ ⁦@UCSDHealth⁩ ⁦@CLDFoundation⁩ - 60 registrations and a waiting list

Kickstarting the ⁦@CLDFoundation⁩ Breakthroughs in MASH Diagnosis and Management in San Diego with ⁦@MASLDResearch⁩ faculty ⁦@AjmeraVeeral⁩ and Lisa Richards, NP tonight with a full house ⁦@AASLDtweets⁩ ⁦@EASLnews⁩ ⁦@UCSD_GI⁩ ⁦